牛牛AI助理已提取核心訊息
Apollomics Inc., a clinical-stage biopharmaceutical company, announced on March 4, 2024, the appointment of Matthew Plunkett, Ph.D., as its new Chief Financial Officer. Dr. Plunkett brings over 25 years of experience in strategic and financial roles within the biopharmaceutical sector, including leading successful IPOs for Aeovian Pharmaceuticals and Nkarta Therapeutics. His expertise is expected to be a significant asset as Apollomics advances its clinical, regulatory, and commercialization plans, particularly for its lead drug candidates vebreltinib and uproleselan. The company, which is traded on Nasdaq under the symbols 'APLM' and 'APLMW', also filed a prospectus supplement to update information in its previous prospectus, including a press release about the new CFO appointment. Apollomics focuses on developing oncology therapies and has a pipeline of nine drug candidates, with six in clinical development. The company's securities are subject to investment risks, detailed on page 25 of the Prospectus. The last reported sale price of Apollomics' shares and warrants on March 1, 2024, was $0.76 per share and $0.03 per warrant, respectively.
Apollomics Inc., a clinical-stage biopharmaceutical company, announced on March 4, 2024, the appointment of Matthew Plunkett, Ph.D., as its new Chief Financial Officer. Dr. Plunkett brings over 25 years of experience in strategic and financial roles within the biopharmaceutical sector, including leading successful IPOs for Aeovian Pharmaceuticals and Nkarta Therapeutics. His expertise is expected to be a significant asset as Apollomics advances its clinical, regulatory, and commercialization plans, particularly for its lead drug candidates vebreltinib and uproleselan. The company, which is traded on Nasdaq under the symbols 'APLM' and 'APLMW', also filed a prospectus supplement to update information in its previous prospectus, including a press release about the new CFO appointment. Apollomics focuses on developing oncology therapies and has a pipeline of nine drug candidates, with six in clinical development. The company's securities are subject to investment risks, detailed on page 25 of the Prospectus. The last reported sale price of Apollomics' shares and warrants on March 1, 2024, was $0.76 per share and $0.03 per warrant, respectively.
處於臨床階段的生物製藥公司Apollomics Inc. 於2024年3月4日宣佈任命馬修·普倫基特博士爲其新任首席財務官。Plunkett博士在生物製藥領域擁有超過25年的戰略和財務職位經驗，包括領導Aeovian Pharmicals和Nkarta Therapeutics的成功首次公開募股。隨着Apollomics推進其臨床、監管和商業化計劃，特別是針對其主要候選藥物vebreltinib和uproleselan的計劃，他的專業知識有望成爲一項重要資產。該公司在納斯達克上市，股票代碼爲 “APLM” 和 “APLMW”，該公司還提交了招股說明書補充文件，以更新其先前的招股說明書中的信息，...展開全部
處於臨床階段的生物製藥公司Apollomics Inc. 於2024年3月4日宣佈任命馬修·普倫基特博士爲其新任首席財務官。Plunkett博士在生物製藥領域擁有超過25年的戰略和財務職位經驗，包括領導Aeovian Pharmicals和Nkarta Therapeutics的成功首次公開募股。隨着Apollomics推進其臨床、監管和商業化計劃，特別是針對其主要候選藥物vebreltinib和uproleselan的計劃，他的專業知識有望成爲一項重要資產。該公司在納斯達克上市，股票代碼爲 “APLM” 和 “APLMW”，該公司還提交了招股說明書補充文件，以更新其先前的招股說明書中的信息，包括有關新首席財務官任命的新聞稿。Apollomics專注於開發腫瘤療法，目前有九種候選藥物在線，其中六種正在臨床開發中。該公司的證券面臨投資風險，詳見招股說明書第25頁。2024年3月1日，Apollomics上次公佈的股票和認股權證的銷售價格分別爲每股0.76美元和每份認股權證0.03美元。
有用
沒用